HOME >> BIOLOGY >> NEWS
Other Highlights in the July 3 Issue of JNCI

Compound Delays Progression of Premalignant Lung Lesions:
A phase IIb study of anethole dithiolethione (ADT) in smokers with bronchial dysplasia (pre-malignant lesions in the lung) suggests that the compound is an effective chemopreventive strategy for lung cancer control. These findings appear in the July 3 issue of the Journal of the National Cancer Institute.

ADT is one of two organosulfur compounds that are being studied for their ability to stimulate the production of enzymes that detoxify carcinogens. ADT has been approved in Canada and Europe for the treatment of drug- and radiation-induced dryness of the mouth and other conditions. To examine the effectiveness of ADT as a chemopreventive agent in lung cancer, Stephen Lam, M.D., of the British Columbia Cancer Agency and the University of British Columbia, and his colleagues randomly assigned 112 current and former smokers with bronchial dysplasia to receive either ADT or a placebo for 6 months.

Compared with patients who received placebo, those who received ADT had a lower rate of progression by two or more grades of preexisting dysplastic lesions and a reduction in the appearance of new lesions. Side effects of ADT were minor and included gastrointestinal symptoms that subsided after dose reduction or completion of ADT treatment.

Vitamin B12 May be Effective Carrier of Anticancer Drug:
Vitamin B12, an essential micronutrient, is required by tumors in increased concentrations compared with normal tissue. Joseph A. Bauer, Ph.D., and Daniel J. Lindler, M.D., Ph.D., of the Cleveland Clinic Foundation, and their colleagues examined whether a vitamin B12 analogue could be used as a carrier molecule to direct a chemotherapy drug to tumor cells.

The authors attached nitric oxide, which is toxic when internalized by cells, to vitamin B12. When mice bearing human tumors were treated with this compound, the tumors regressed. However, when the mice
'"/>

Contact: Linda Wang
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
2-Jul-2002


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 18 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Other Highlights the July Issue JNCI

(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/27/2015)... 27, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... 2015. Aviv Boim , CEO ... work to generate functional specific antibodies, targeting identified cancer ... are encouraged by the development progress. We are excited ... which modulate immune checkpoints gain clinical acceptance for cancer ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... update on the status of the Company,s Series ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... and 21 shares of Series A Preferred Stock ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
Cached News: